Logo image of ZYXI

ZYNEX INC (ZYXI) Stock Fundamental Analysis

NASDAQ:ZYXI - Nasdaq - US98986M1036 - Common Stock - Currency: USD

2.4  -0.29 (-10.78%)

After market: 2.35 -0.05 (-2.08%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZYXI. ZYXI was compared to 187 industry peers in the Health Care Equipment & Supplies industry. ZYXI has an average financial health and profitability rating. ZYXI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ZYXI had negative earnings in the past year.
ZYXI had a positive operating cash flow in the past year.
Each year in the past 5 years ZYXI has been profitable.
ZYXI had a positive operating cash flow in each of the past 5 years.
ZYXI Yearly Net Income VS EBIT VS OCF VS FCFZYXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.01%, ZYXI is in the better half of the industry, outperforming 64.71% of the companies in the same industry.
Looking at the Return On Equity, with a value of -35.68%, ZYXI is in line with its industry, outperforming 52.41% of the companies in the same industry.
Industry RankSector Rank
ROA -7.01%
ROE -35.68%
ROIC N/A
ROA(3y)8.05%
ROA(5y)9.92%
ROE(3y)18.36%
ROE(5y)18.84%
ROIC(3y)N/A
ROIC(5y)N/A
ZYXI Yearly ROA, ROE, ROICZYXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

In the last couple of years the Profit Margin of ZYXI has declined.
In the last couple of years the Operating Margin of ZYXI has declined.
ZYXI has a Gross Margin of 77.84%. This is amongst the best in the industry. ZYXI outperforms 91.98% of its industry peers.
ZYXI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ZYXI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.84%
OM growth 3Y-43.42%
OM growth 5Y-33.75%
PM growth 3Y-50.87%
PM growth 5Y-40.5%
GM growth 3Y0.14%
GM growth 5Y-0.29%
ZYXI Yearly Profit, Operating, Gross MarginsZYXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

ZYXI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZYXI has less shares outstanding
Compared to 5 years ago, ZYXI has less shares outstanding
The debt/assets ratio for ZYXI is higher compared to a year ago.
ZYXI Yearly Shares OutstandingZYXI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ZYXI Yearly Total Debt VS Total AssetsZYXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.62 indicates that ZYXI is not a great score, but indicates only limited risk for bankruptcy at the moment.
ZYXI has a Altman-Z score of 2.62. This is in the better half of the industry: ZYXI outperforms 64.71% of its industry peers.
ZYXI has a Debt/Equity ratio of 2.87. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.87, ZYXI is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF N/A
Altman-Z 2.62
ROIC/WACCN/A
WACC7.74%
ZYXI Yearly LT Debt VS Equity VS FCFZYXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

ZYXI has a Current Ratio of 3.46. This indicates that ZYXI is financially healthy and has no problem in meeting its short term obligations.
ZYXI has a Current ratio of 3.46. This is in the better half of the industry: ZYXI outperforms 62.03% of its industry peers.
ZYXI has a Quick Ratio of 2.63. This indicates that ZYXI is financially healthy and has no problem in meeting its short term obligations.
ZYXI has a Quick ratio of 2.63. This is comparable to the rest of the industry: ZYXI outperforms 59.36% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 2.63
ZYXI Yearly Current Assets VS Current LiabilitesZYXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ZYXI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -160.00%.
Measured over the past years, ZYXI shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -18.77% on average per year.
ZYXI shows a decrease in Revenue. In the last year, the revenue decreased by -8.63%.
The Revenue has been growing by 33.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-160%
EPS 3Y-41.04%
EPS 5Y-18.77%
EPS Q2Q%-109766.67%
Revenue 1Y (TTM)-8.63%
Revenue growth 3Y13.86%
Revenue growth 5Y33.42%
Sales Q2Q%-42.88%

3.2 Future

The Earnings Per Share is expected to decrease by -4.52% on average over the next years.
ZYXI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.87% yearly.
EPS Next Y-987.77%
EPS Next 2Y-148.86%
EPS Next 3Y-51.61%
EPS Next 5Y-4.52%
Revenue Next Year-41.75%
Revenue Next 2Y-16.55%
Revenue Next 3Y-3.5%
Revenue Next 5Y4.87%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ZYXI Yearly Revenue VS EstimatesZYXI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ZYXI Yearly EPS VS EstimatesZYXI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZYXI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZYXI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYXI Price Earnings VS Forward Price EarningsZYXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYXI Per share dataZYXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as ZYXI's earnings are expected to decrease with -51.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-148.86%
EPS Next 3Y-51.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYXI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYNEX INC

NASDAQ:ZYXI (7/3/2025, 8:19:27 PM)

After market: 2.35 -0.05 (-2.08%)

2.4

-0.29 (-10.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)07-24 2025-07-24/amc
Inst Owners22.41%
Inst Owner Change-15.49%
Ins Owners48.39%
Ins Owner Change-6.4%
Market Cap72.58M
Analysts77.78
Price Target6.12 (155%)
Short Float %25.44%
Short Ratio16.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-65.69%
DP-0.08%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.3%
Min EPS beat(2)-121.79%
Max EPS beat(2)-34.8%
EPS beat(4)1
Avg EPS beat(4)-46.09%
Min EPS beat(4)-121.79%
Max EPS beat(4)21.1%
EPS beat(8)4
Avg EPS beat(8)-20.26%
EPS beat(12)8
Avg EPS beat(12)4.13%
EPS beat(16)11
Avg EPS beat(16)4.96%
Revenue beat(2)0
Avg Revenue beat(2)-15.74%
Min Revenue beat(2)-15.99%
Max Revenue beat(2)-15.48%
Revenue beat(4)0
Avg Revenue beat(4)-10.3%
Min Revenue beat(4)-15.99%
Max Revenue beat(4)-3.62%
Revenue beat(8)0
Avg Revenue beat(8)-7.97%
Revenue beat(12)1
Avg Revenue beat(12)-5.46%
Revenue beat(16)1
Avg Revenue beat(16)-4.88%
PT rev (1m)0%
PT rev (3m)-41.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-290.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-264.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-51.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF 483.84
P/B 3.49
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFY0.21%
SpS5.7
BVpS0.69
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.01%
ROE -35.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.84%
FCFM N/A
ROA(3y)8.05%
ROA(5y)9.92%
ROE(3y)18.36%
ROE(5y)18.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)12.93%
ROCE(5y)15.14%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-43.42%
OM growth 5Y-33.75%
PM growth 3Y-50.87%
PM growth 5Y-40.5%
GM growth 3Y0.14%
GM growth 5Y-0.29%
F-Score4
Asset Turnover1.63
Health
Industry RankSector Rank
Debt/Equity 2.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.41%
Cap/Sales 0.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 2.63
Altman-Z 2.62
F-Score4
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)18.03%
Cap/Depr(5y)28.76%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.58%
Profit Quality(3y)218.02%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160%
EPS 3Y-41.04%
EPS 5Y-18.77%
EPS Q2Q%-109766.67%
EPS Next Y-987.77%
EPS Next 2Y-148.86%
EPS Next 3Y-51.61%
EPS Next 5Y-4.52%
Revenue 1Y (TTM)-8.63%
Revenue growth 3Y13.86%
Revenue growth 5Y33.42%
Sales Q2Q%-42.88%
Revenue Next Year-41.75%
Revenue Next 2Y-16.55%
Revenue Next 3Y-3.5%
Revenue Next 5Y4.87%
EBIT growth 1Y-169.24%
EBIT growth 3Y-35.57%
EBIT growth 5Y-11.61%
EBIT Next Year-118.41%
EBIT Next 3Y-35.35%
EBIT Next 5Y14.23%
FCF growth 1Y-103.31%
FCF growth 3Y24.19%
FCF growth 5Y14.61%
OCF growth 1Y-98.92%
OCF growth 3Y22.32%
OCF growth 5Y15.09%